Endogun tests new product

Endogun Medical Systems Ltd. announced that is has launched a human clinical study for the treatment of Pelvic Organ Prolapse, which occurs in women often following births or significant weight loss, and develops as a result of weakening of the pelvic muscles which support internal organs.

By MATTHEW KRIEGER
March 14, 2007 07:40

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Endogun Medical Systems Ltd. announced this week that is has launched a human clinical study for the treatment of Pelvic Organ Prolapse, which occurs in women often following births or significant weight loss, and develops as a result of weakening of the pelvic muscles which support internal organs. The company claims its solution has significant advantages over what is currently available and will increase the safety and overall costs associated with prolapse repair. Kiryat Shmona-based Endogun manufactures products for minimally-invasive fastening of soft-tissue, and has completed two rounds of financing for its prolapse product, led by Pontifax Funds, founded by Teva Pharmaceutical Industries CEO Eli Hurvitz.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS